Ito M, Miyata Y, Tsutani Y, et al. - Researchers examined the prognostic influence of EGFR mutation status in relation to pStage (pathological stage) and histological subtype in resected pN0–1M0 lung adenocarcinoma, in a retrospective manner by utilizing a multicenter database. There were 1,155 pN0–1M0 adenocarcinoma cases in total. Among those, pStage 0 and IA1–IB were verified mainly in EGFR-positive cases. EGFR-positive cases more often had AIS, MIA, and lepidic predominant adenocarcinoma. Irrespective of EGFR mutation status, no/little recurrence was reported for AIS, MIA, and lepidic predominant adenocarcinoma. Findings revealed that EGFR mutation harbored principally in early-stage or low-malignant histological subtypes with no/little recurrence. Worse recurrence-free survival was reported for positive EGFR mutation cases in pN0–1M0 adenocarcinoma with a higher risk of recurrence. Recurrence risk was better stratified with the help of EGFR mutation status when taking pStage and histological malignant subtype into account.